News
CRMD
8.40
-3.11%
-0.27
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 2d ago
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
NASDAQ · 3d ago
CorMedix Price Target Cut to $13.00/Share From $14.00 by RBC Capital
Dow Jones · 4d ago
CorMedix Is Maintained at Outperform by RBC Capital
Dow Jones · 4d ago
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13
Benzinga · 4d ago
The Math Shows IHE Can Go To $110
NASDAQ · 5d ago
Weekly Report: what happened at CRMD last week (0629-0703)?
Weekly Report · 6d ago
Cormedix Restructures Leadership, Expands Operating and Commercial Role
TipRanks · 07/02 21:07
CorMedix names Elizabeth Hurlburt chief operating and commercial officer
PUBT · 07/02 20:33
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 07/01 12:02
CorMedix switches auditor, names Ernst & Young for 2026 audit
PUBT · 07/01 11:14
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
NASDAQ · 06/30 15:10
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
NASDAQ · 06/30 15:07
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
NASDAQ · 06/30 15:04
Weekly Report: what happened at CRMD last week (0622-0626)?
Weekly Report · 06/29 09:29
CorMedix Shareholders Reject Governance Changes at Annual Meeting
TipRanks · 06/24 21:03
CorMedix holds annual shareholder meeting
PUBT · 06/24 20:34
Weekly Report: what happened at CRMD last week (0615-0619)?
Weekly Report · 06/22 09:33
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
Seeking Alpha · 06/18 11:43
These small-cap healthcare stocks pair revenue growth with attractive valuations
Seeking Alpha · 06/17 11:02
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.